Economic evaluation for the US of durvalumab plus gemcitabine and cisplatin (DGC) in advanced biliary tract cancer (BTC)

被引：0
|
作者：
Aqel, Osama
Shen, Yunrong
Alfayoumi, Ibrahim
Abraham, Ivo
机构：
[1] Univ Arizona, Ctr Hlth Outcomes & Pharmacoecon Res, Tucson, AZ USA
[2] Univ Arizona Pharm, Dept Pharm Practice & Sci, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4081
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
    Valle, Juan
    Wasan, Harpreet
    Palmer, Daniel H.
    Cunningham, David
    Anthoney, Alan
    Maraveyas, Anthony
    Madhusudan, Srinivasan
    Iveson, Tim
    Hughes, Sharon
    Pereira, Stephen P.
    Roughton, Michael
    Bridgewater, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (14): : 1273 - 1281
  • [22] Selumetinib (Sel) and cisplatin/gemcitabine (CisGem) for advanced biliary tract cancer (BTC): A randomized trial.
    Doherty, Mark
    Tam, Vincent C.
    McNamara, Mairead Geraldine
    Hedley, David W.
    Dhani, Neesha C.
    Chen, Eric Xueyu
    Jang, Raymond Woo-Jun
    Tang, Patricia A.
    Sim, Hao-Wen
    O'Kane, Grainne M.
    DeLuca, Stephanie
    Wang, Lisa
    Brooks, Kelly
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer: a phase II study
    不详
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (5) : 280 - 280
  • [24] Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer: a phase II study
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 280 - 280
  • [25] Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
    Valle, J. W.
    Qin, S.
    Antonuzzo, L.
    Tougeron, D.
    Lee, C-K.
    Tan, B. J.
    Ikeda, M.
    Guthrie, V.
    McCoon, P.
    Lee, Y. S.
    Rokutanda, N.
    Zotkiewicz, M.
    Cohen, G.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1457 - S1457
  • [26] Impact of mutation status on efficacy outcomes in TOPAZ-1: A Phase 3 study of Durvalumab (D) or Placebo (PBO) plus Gemcitabine and Cisplatin ( plus GC) in advanced Biliary Tract Cancer (BTC)
    Vogel, A.
    Valle, J.
    Qin, S.
    Antonuzo, L.
    Tougeron, D.
    Lee, C. -K.
    Tan, B.
    Ikeda, M.
    Guthrie, V.
    McCoon, P.
    Lee, Y.
    Rokutanda, N.
    Watras, M.
    Cohen, G.
    Oh, D. -Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 63 - 64
  • [27] Impact of mutation status on efficacy outcomes in TOPAZ-1: A Phase 3 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
    Vogel, Arndt
    Valle, Juan
    Qin, Shukui
    Antonuzzo, Lorenzo
    Tougeron, David
    Lee, Choongkun
    Tan, Benjamin
    Ikeda, Masafumi
    Guthrie, Violeta
    Mccoon, Patricia
    Lee, Young
    Rokutanda, Nana
    Zotkiewicz, Magdalena
    Cohen, Gordon
    Oh, Do-Youn
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 68 - 68
  • [28] Real-world data of durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: A Thailand multicenter observational study
    Tanasanvimon, Suebpong
    Maneenil, Kunlatida
    Wirasorn, Kosin
    Thanasombunsukh, Kijjakom
    Korphaisarn, Krittiya
    Sathitruangsak, Chirawadee
    Wanchaijiraboon, Passakorn
    Siripoon, Teerada
    Teeyapan, Nattaya
    Charonpongsuntorn, Chanchai
    Suksombooncharoen, Thatthan
    Thambamroong, Tawasapon
    Laosuangkoon, Wannisa
    Ngokngarm, Chavapon
    Simseekeaw, Pronwasun
    Akewanlop, Charuwan
    Sirachainan, Ekaphop
    TSCO GI Grp
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 607 - 607
  • [29] Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer
    Ahn, Daniel H.
    Reardon, Josh
    Ahn, Chul W.
    Bupathi, Manojkumar
    Mikhail, Sameh
    Wu, Christina Sing-Ying
    Bekaii-Saab, Tanios
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (08) : 1671 - 1675
  • [30] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer
    Finkelmeier, Fabian
    Bouattour, Mohamed
    Valle, Juan
    Vogel, Arndt
    Kim, Jin Won
    Kitano, Masayuki
    Chen, Jen-Shi
    Burris, Howard
    Zaucha, Renata
    Qin, Shukui
    Evesque, Ludovic
    Zhen, David B.
    Gupta, Vineet Govinda
    Park, Joon Oh
    Zotkiewicz, Magdalena
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 63 - 64
12345